12 Month Price Forecast For DRTS
Distance to DRTS Price Forecasts
DRTS Price Momentum
๐ค Considering Alpha Tau (DRTS)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 15, 2025 1:41 PM UTC
DRTS Analyst Ratings & Price Targets
Based on our analysis of 5 Wall Street analysts, DRTS has a bullish consensus with a median price target of $8.50 (ranging from $5.00 to $13.00). Currently trading at $3.14, the median forecast implies a 170.7% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DRTS Analyst Consensus
DRTS Price Target Range
Latest DRTS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DRTS.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Nov 22, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $9.00 |
Oct 23, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $9.00 |
Oct 11, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $9.00 |
Aug 20, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $9.00 |
Aug 15, 2024 | Piper Sandler | Jason Bednar | Overweight | Reiterates | $7.00 |
Jun 26, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $9.00 |
May 22, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $9.00 |
May 16, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $9.00 |
Mar 12, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $9.00 |
Mar 8, 2024 | Piper Sandler | Jason Bednar | Overweight | Reiterates | $7.00 |
Dec 15, 2023 | Citigroup | Ashiq Mubarack | Buy | Initiates | $8.00 |
Nov 20, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $9.00 |
Nov 17, 2023 | Piper Sandler | Jason Bednar | Overweight | Maintains | $8.00 |
Sep 20, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $9.00 |
Aug 29, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $9.00 |
Aug 29, 2023 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $23.00 |
Aug 18, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $9.00 |
May 24, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $9.00 |
May 18, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $9.00 |
May 15, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $9.00 |
Stocks Similar to Alpha Tau Medical Ltd.
The following stocks are similar to Alpha Tau based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Alpha Tau Medical Ltd. (DRTS) Financial Data
Alpha Tau Medical Ltd. has a market capitalization of $220.47M with a P/E ratio of -7.5x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -37.2%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Alpha Tau Medical Ltd. (DRTS) Company Overview
About Alpha Tau Medical Ltd.
Develops innovative cancer radiation therapy.
The company focuses on the research, development, and commercialization of its proprietary Alpha-DaRT technology. This therapy utilizes diffusing alpha-emitters for targeted radiation treatment of various solid tumors, generating revenue through clinical trial advancements and potential future product sales.
Alpha Tau Medical is currently in the clinical trial stage for multiple cancer types, including skin, oral, pancreatic, prostate, lung, liver, and breast cancers. Founded in 2015 and headquartered in Jerusalem, Israel, the company is expanding its research to address additional cancers, indicating potential growth in both treatment options and market reach.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
121
CEO
Mr. Uzi Sofer
Country
Israel
IPO Year
2021
Website
www.alphatau.comAlpha Tau Medical Ltd. (DRTS) Latest News & Analysis
Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day
19 days agoAlpha DaRTยฎ shows high disease control rates and strong interim safety results in pancreatic cancer patients across three trials.
Promising trial results for Alpha DaRT in pancreatic cancer could indicate a potential breakthrough treatment, influencing stock valuations and future investment in biotech firms involved.
Alpha Tau Medical Ltd. announced the appointment of Ms. Maya Netser to its Board of Directors, replacing Mr. Meir Jakobsohn, who will serve in an advisory role after his term ends.
Board changes can signal strategic shifts or new directions for a company. Maya Netser's appointment may influence Alpha Tau's future strategies, impacting investor sentiment and stock performance.
Alpha Tau Medical's study on its alpha-radiation therapy for pancreatic cancer will be presented at the 2025 ASCO Gastrointestinal Cancers Symposium on January 24, 2025.
The acceptance of Alpha Tau's trial results for presentation at a major oncology symposium highlights credibility and potential market interest, which could influence stock performance and investor sentiment.
The company's upcoming presentation will highlight recent achievements and provide insights on future data milestones.
The presentation highlights the company's recent successes and future data milestones, which can impact stock performance and investor sentiment. Positive achievements may boost confidence and valuations.
Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW) announced that CFO Raphi Levy will present at the Ladenburg Oncology Innovators & Investors Symposium on December 6, 2024.
CFO Raphi Levy's presentation at a key oncology symposium could enhance Alpha Tau's visibility, attract investor interest, and potentially impact stock performance due to new insights or partnerships.
Alpha Tau Medical's CFO Raphi Levy will speak at the Citi Global Healthcare Conference on December 3, 2024, and the Piper Sandler Healthcare Conference on December 5, 2024.
CFO participation in major healthcare conferences can signal potential growth and investment interest, indicating Alpha Tau's strategic positioning in the cancer therapy market.
Frequently Asked Questions About DRTS Stock
What is Alpha Tau Medical Ltd.'s (DRTS) stock forecast for 2025?
Based on our analysis of 5 Wall Street analysts, Alpha Tau Medical Ltd. (DRTS) has a median price target of $8.50. The highest price target is $13.00 and the lowest is $5.00.
Is DRTS stock a good investment in 2025?
According to current analyst ratings, DRTS has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.14. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for DRTS stock?
Wall Street analysts predict DRTS stock could reach $8.50 in the next 12 months. This represents a 170.7% increase from the current price of $3.14. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Alpha Tau Medical Ltd.'s business model?
The company focuses on the research, development, and commercialization of its proprietary Alpha-DaRT technology. This therapy utilizes diffusing alpha-emitters for targeted radiation treatment of various solid tumors, generating revenue through clinical trial advancements and potential future product sales.
What is the highest forecasted price for DRTS Alpha Tau Medical Ltd.?
The highest price target for DRTS is $13.00 from at , which represents a 314.0% increase from the current price of $3.14.
What is the lowest forecasted price for DRTS Alpha Tau Medical Ltd.?
The lowest price target for DRTS is $5.00 from at , which represents a 59.2% increase from the current price of $3.14.
What is the overall DRTS consensus from analysts for Alpha Tau Medical Ltd.?
The overall analyst consensus for DRTS is bullish. Out of 5 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $8.50.
How accurate are DRTS stock price projections?
Stock price projections, including those for Alpha Tau Medical Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.